Business and Organization (Details) $ / shares in Units, $ in Thousands				3 Months Ended
	Apr. 12, 2023 shares	May 09, 2022 USD ($) $ / shares shares	Apr. 29, 2022 USD ($) $ / shares shares	Mar. 31, 2023 employee $ / shares shares	Dec. 31, 2022 $ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of sales employees | employee				180
Common stock, par value (in dollars per share) | $ / shares				$ 0.01	$ 0.01
GeneDx Holdings | Common Class A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Investment owned (in shares) | shares			80,000,000	94,300,000
Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of shares included in consideration from GeneDx Holdings		$ 221,700
Stock price (in dollars per share) | $ / shares		$ 2.44
ModeX Therapeutics Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total aggregate consideration		$ 300,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.01
Shares deposited in escrow (as a percent)		10.00%
Escrow deposit, term		12 months
Business acquisition, equity awards issued		$ 12,400
Equity interest issued or issuable, period following closing date		4 years
Escrow period		4 years
Total purchase price		$ 221,662
Vested equity awards		2,300
ModeX Therapeutics Inc | Former Stockholder
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, equity awards issued		$ 2,600
ModeX Therapeutics Inc | Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shares issued in business combination (in shares) | shares		89,907,310
Fair value of shares included in consideration from GeneDx Holdings		$ 219,400
Stock price (in dollars per share) | $ / shares		$ 2.44
Detect Genomix | Milestone Consideration, Tranche One
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period			1 year
Detect Genomix | Milestone Consideration, Tranche Two
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period			6 months
Detect Genomix | GeneDx Holdings
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Payments to acquire business			$ 150,000
Total upfront consideration transferred			$ 322,000
Maximum earnout payment (in shares) | shares			30,900,000
Business acquisition, outstanding shares held, percentage			5.00%
Detect Genomix | GeneDx Holdings | Common Class A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value (in dollars per share) | $ / shares			$ 0.0001
Detect Genomix | GeneDx Holdings | Common Class A | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shares issued in business combination (in shares) | shares	23,100,000